IRAY TECHNOLOGY COMPANY LIMITED Financials iRay Technology Company Limited
Equities
688301
CNE1000042V8
Advanced Medical Equipment & Technology
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 107.6 CNY | +2.52% |
|
-6.60% | -53.67% |
| May. 24 | IRay Technology Company Limited announced a financing transaction | CI |
| Apr. 30 | Nomura Adjusts iRay Technology’s Price Target to 245.69 Yuan From 285.80 Yuan, Keeps at Buy | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 12,456 | 36,049 | 33,284 | 33,157 | 15,348 | - | - |
| Enterprise Value (EV) 1 | 12,456 | 36,049 | 31,900 | 33,258 | 13,123 | 12,710 | 13,269 |
| P/E ratio | 45.5 x | 74.5 x | 52 x | 56.6 x | 18.1 x | 14.3 x | 12.5 x |
| Yield | - | 0.44% | 0.63% | 0.61% | 1.88% | 2.16% | 2.75% |
| Capitalization / Revenue | 15.9 x | 30.4 x | 21.5 x | 17.8 x | 6.53 x | 5.22 x | 4.48 x |
| EV / Revenue | 15.9 x | 30.4 x | 20.6 x | 17.8 x | 5.58 x | 4.32 x | 3.87 x |
| EV / EBITDA | 44.9 x | 61.7 x | 43.1 x | 45.4 x | 12.7 x | 9.3 x | 7.45 x |
| EV / FCF | - | 640 x | -79.6 x | -22 x | -36.4 x | 28.4 x | 7.64 x |
| FCF Yield | - | 0.16% | -1.26% | -4.54% | -2.75% | 3.52% | 13.1% |
| Price to Book | 4.73 x | 11.8 x | 9.19 x | 8.14 x | 3.01 x | 2.56 x | 2.32 x |
| Nbr of stocks (in thousands) | 142,194 | 142,194 | 142,475 | 142,718 | 142,599 | - | - |
| Reference price 2 | 87.60 | 253.5 | 233.6 | 232.3 | 107.6 | 107.6 | 107.6 |
| Announcement Date | 2/23/21 | 2/24/22 | 2/23/23 | 4/19/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 784.1 | 1,187 | 1,549 | 1,864 | 2,350 | 2,943 | 3,429 |
| EBITDA 1 | 277.7 | 584 | 739.9 | 732.7 | 1,034 | 1,367 | 1,780 |
| EBIT 1 | 246.4 | 549.9 | 708.7 | 683.6 | 921.6 | 1,151 | 1,360 |
| Operating Margin | 31.42% | 46.31% | 45.75% | 36.68% | 39.21% | 39.1% | 39.67% |
| Earnings before Tax (EBT) 1 | 254.6 | 559.9 | 708.7 | 685 | 947.6 | 1,196 | 1,393 |
| Net income 1 | 225.3 | 484 | 641.3 | 607.5 | 838.7 | 1,067 | 1,231 |
| Net margin | 28.73% | 40.77% | 41.4% | 32.59% | 35.68% | 36.27% | 35.9% |
| EPS 2 | 1.923 | 3.403 | 4.495 | 4.107 | 5.957 | 7.544 | 8.624 |
| Free Cash Flow 1 | - | 56.36 | -400.7 | -1,510 | -361 | 448 | 1,736 |
| FCF margin | - | 4.75% | -25.87% | -81.04% | -15.36% | 15.22% | 50.62% |
| FCF Conversion (EBITDA) | - | 9.65% | - | - | - | 32.77% | 97.51% |
| FCF Conversion (Net income) | - | 11.64% | - | - | - | 41.97% | 141.02% |
| Dividend per Share 2 | - | 1.122 | 1.480 | 1.429 | 2.023 | 2.320 | 2.957 |
| Announcement Date | 2/23/21 | 2/24/22 | 2/23/23 | 4/19/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 S1 | 2021 Q4 | 2021 S2 | 2022 S1 | 2022 Q4 | 2022 S2 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales | - | 363.6 | 631.7 | - | 445.2 | 828.5 | - | - | - | - | 466.9 | 490.9 | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT | - | 191 | 316.2 | - | 146.8 | 413.3 | - | - | - | - | 204.1 | - | - | - | - |
| Operating Margin | - | 52.53% | 50.05% | - | 32.98% | 49.89% | - | - | - | - | 43.72% | - | - | - | - |
| Earnings before Tax (EBT) | - | 193.8 | 324.4 | - | 146.7 | 413.2 | - | 216.2 | 364.9 | - | 204.5 | 154.2 | - | - | - |
| Net income | 209.8 | 158.2 | 274.3 | 276.4 | 133.3 | 364.9 | - | 187.9 | 324.6 | - | 174.6 | 139.3 | - | - | - |
| Net margin | - | 43.51% | 43.42% | - | 29.95% | 44.04% | - | - | - | - | 37.39% | 28.37% | - | - | - |
| EPS 1 | 1.474 | 1.112 | 1.929 | 1.944 | 0.9235 | 2.551 | 1.157 | 1.114 | - | 0.7571 | 1.071 | 0.9286 | 1.421 | 1.171 | 1.893 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/4/21 | 2/24/22 | 2/24/22 | 8/28/22 | 2/23/23 | 2/23/23 | 4/26/23 | 8/28/23 | 8/28/23 | 10/14/23 | 4/19/24 | 4/29/24 | - | - | - |
1CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 101 | - | - | - |
| Net Cash position 1 | - | - | 1,384 | - | 2,224 | 2,638 | 2,079 |
| Leverage (Debt/EBITDA) | - | - | - | 0.1375 x | - | - | - |
| Free Cash Flow 1 | - | 56.4 | -401 | -1,510 | -361 | 448 | 1,736 |
| ROE (net income / shareholders' equity) | 21.8% | 17% | 19.3% | 15% | 17.4% | 18.4% | 18.6% |
| ROA (Net income/ Total Assets) | - | 15% | 13.7% | 8.3% | 9.5% | 11.8% | 11.6% |
| Assets 1 | - | 3,228 | 4,678 | 7,315 | 8,826 | 9,011 | 10,603 |
| Book Value Per Share 2 | 18.50 | 21.50 | 25.40 | 28.60 | 35.70 | 42.00 | 46.40 |
| Cash Flow per Share 2 | 1.840 | 1.740 | 2.220 | 2.380 | 3.640 | 9.770 | 8.020 |
| Capex 1 | - | 192 | 717 | 1,851 | 393 | 444 | 435 |
| Capex / Sales | - | 16.14% | 46.31% | 99.3% | 16.73% | 15.08% | 12.69% |
| Announcement Date | 2/23/21 | 2/24/22 | 2/23/23 | 4/19/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
107.6
CNY
Average target price
206.7
CNY
Spread / Average Target
+92.08%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -53.67% | 2.11B | |
| -21.16% | 12.18B | |
| -24.52% | 2.12B | |
| -28.16% | 1.19B | |
| -.--% | 1.12B | |
| +93.33% | 513M | |
| +7.38% | 395M | |
| +29.20% | 281M | |
| -18.19% | 186M | |
| +3.33% | 186M |
- Stock Market
- Equities
- 688301 Stock
- Financials iRay Technology Company Limited
